It's probably true that a company would be hard-pressed to do worse than Hospira (HSP) has managed in recent years, but it doesn't automatically follow that conditions will get quite a bit better. Hospira certainly could be a better company in a few years' time, but "could" is a dangerous word when it comes to investing. So although I am bullish on Hospira's opportunities in biosimilars, I struggle to come up with a scenario where this stock is priced to outperform.
Q4 Not Really The Problem
With that very bearish intro in hand, Hospira's fourth quarter results actually weren't all that bad. Revenue rose 8% and registered a slight beat relative to analyst expectations. Hospira's specialty injectables business...
Only subscribers can access this article, which is part of the PRO research library covering 3,575 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: